Co-delivery of endoplasmic reticulum-targeted photosensitizer and Ido-1 inhibitor potentiates immunotherapeutic efficacy in triple-negative breast cancer

Jia Wang, Fengling Wang, Qiang Zhou, Yue Huang, Mengjun Yu, Shiwen Chen, Jing Gong, Min Yang, Qiang He, Jingbin Huang, Yu Zhao · 2026

Read Co-delivery of endoplasmic reticulum-targeted photosensitizer and Ido-1 inhibitor potentiates immunotherapeutic efficacy in triple-negative breast cancer by Jia Wang, Fengling Wang, Qiang Zhou, Yue Huang, Mengjun Yu, Shiwen Chen, Jing Gong, Min Yang, Qiang He, Jingbin Huang, Yu Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13241888.txt.

Description

Jia Wang and a large team report a 2026 nanoparticle study for triple-negative breast cancer, a type that responds poorly to immunotherapy. Their particle carries two agents: a light-activated drug that targets the cell protein-folding compartment, and an inhibitor of an enzyme tumors use to dodge immunity.

The carrier homes to tumors through a targeting peptide. Light triggers the first drug to produce reactive oxygen inside the target compartment, killing cells in a way that alerts the immune system. The second drug blocks a metabolic escape route at the same time. In mice, tumors shrank sharply, killer T cell entry rose, and suppressive cells fell, with no visible whole-body toxicity. The authors propose the pairing as a durable immunity strategy.

Catalog record

CREATORJia Wang, Fengling Wang, Qiang Zhou, Yue Huang, Mengjun Yu, Shiwen Chen, Jing Gong, Min Yang, Qiang He, Jingbin Huang, Yu Zhao
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13241888

Browse the full library · About the Tower of Babel